Clinical Trial Update: PROTECT-2: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function [Phase 3]

View source ↗

Summary

Phase 3 trial PROTECT-2 evaluated KW-3902, a selective A1 adenosine receptor antagonist, in patients hospitalized with acute heart failure and volume overload t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Decompensated Heart Failure
• Heart Failure

Drugs mentioned

• KW-3902

Snippet

Sponsor: NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Heart Failure, Congestive | Phase 3 | Status: COMPLETED